In the BioHarmony Drug Report Database

"Preview" Icon

Carmustine

Bicnu, Gliadel (carmustine) is a small molecule pharmaceutical. Carmustine was first approved as Bicnu on 1982-01-01. It is used to treat brain neoplasms, carcinoma, colonic neoplasms, ependymoma, and glioblastoma amongst others in the USA. It has been approved in Europe to treat hodgkin disease and non-hodgkin lymphoma. The pharmaceutical is active against glutathione reductase, mitochondrial.

 

Trade Name

 

Bicnu, Gliadel
 

Common Name

 

carmustine
 

ChEMBL ID

 

CHEMBL513
 

Indication

 

brain neoplasms, carcinoma, colonic neoplasms, ependymoma, glioblastoma, hodgkin disease, lung neoplasms, medulloblastoma, melanoma, multiple myeloma, non-hodgkin lymphoma
 

Drug Class

 

Antineoplastics (chloroethylamine derivatives)

Image (chem structure or protein)

Carmustine structure rendering